Literature DB >> 18164259

Quantitative differences in chromatin accessibility across regulatory regions can be directly compared in distinct cell-types.

Mark Cruickshank1, Emily Fenwick, Lawrence J Abraham, Daniela Ulgiati.   

Abstract

Transcriptional activation in eukaryotes is often accompanied by alterations to chromatin structure at specific regulatory sites while other genomic regions may remain unchanged. In this study, we have examined the correlation between expression and chromatin accessibility of the human CR2 gene in a panel of cell lines (U937, REH, Ramos, and Raji) using the CHART-PCR assay with the accessibility agent micrococcal nuclease (MNase). To validate the use of this assay for comparing multiple cell-types, we first tested a series of genomic regions to determine if we could observe consistent, site-specific levels of MNase chromatin accessibility. Promoter regions of the ubiquitously expressed genes GAPDH and beta-actin were similar and showed high accessibility to MNase digestion in each of the cell lines, while on the other hand, promoter regions of developmentally restricted genes PAX-7 and SP-A2 showed consistently reduced chromatin accessibility. Since CHART-PCR detected site-specific differences in chromatin accessibility in a manner that could be compared between cell-types, we next examined chromatin accessibility over the CR2 core promoter in the panel of cell lines representing either CR2 expressing or CR2 non-expressing cell-types. Our data revealed significantly enhanced accessibility over the -289 to -101 and the -115 to -12 regions of the CR2 promoter in expressing B-cells (Ramos, Raji) compared to non-expressing cells (U937, REH). Thus, CHART-PCR assays detected a correlation between chromatin accessibility and expression of the human CR2 gene, while the accessibility of other genomic regions was site-specific, but not altered between cell-types.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18164259     DOI: 10.1016/j.bbrc.2007.12.121

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  De-regulated expression of the BRG1 chromatin remodeling factor in bone marrow mesenchymal stromal cells induces senescence associated with the silencing of NANOG and changes in the levels of chromatin proteins.

Authors:  Tiziana Squillaro; Valeria Severino; Nicola Alessio; Annarita Farina; Giovanni Di Bernardo; Marilena Cipollaro; Gianfranco Peluso; Angela Chambery; Umberto Galderisi
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Transcriptional effects of a lupus-associated polymorphism in the 5' untranslated region (UTR) of human complement receptor 2 (CR2/CD21).

Authors:  Mark N Cruickshank; Mahdad Karimi; Rhonda L Mason; Emily Fenwick; Tim Mercer; Betty P Tsao; Susan A Boackle; Daniela Ulgiati
Journal:  Mol Immunol       Date:  2012-06-04       Impact factor: 4.407

3.  Molecular prioritization strategies to identify functional genetic variants in the cardiovascular disease-associated expression QTL Vanin-1.

Authors:  Belinda J Kaskow; Luke A Diepeveen; J Michael Proffitt; Alexander J Rea; Daniela Ulgiati; John Blangero; Eric K Moses; Lawrence J Abraham
Journal:  Eur J Hum Genet       Date:  2013-09-18       Impact factor: 4.246

4.  SWI/SNF chromatin remodeling enzymes are associated with cardiac hypertrophy in a genetic rat model of hypertension.

Authors:  Aanchal Mehrotra; Bina Joe; Ivana L de la Serna
Journal:  J Cell Physiol       Date:  2013-12       Impact factor: 6.384

5.  Epigenomic signatures underpin the axonal regenerative ability of dorsal root ganglia sensory neurons.

Authors:  Ilaria Palmisano; Matt C Danzi; Thomas H Hutson; Luming Zhou; Eilidh McLachlan; Elisabeth Serger; Kirill Shkura; Prashant K Srivastava; Arnau Hervera; Nick O' Neill; Tong Liu; Hassen Dhrif; Zheng Wang; Miroslav Kubat; Stefan Wuchty; Matthias Merkenschlager; Liron Levi; Evan Elliott; John L Bixby; Vance P Lemmon; Simone Di Giovanni
Journal:  Nat Neurosci       Date:  2019-10-07       Impact factor: 24.884

6.  Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases.

Authors:  Fayza Daboussi; Mikhail Zaslavskiy; Laurent Poirot; Mariana Loperfido; Agnès Gouble; Valerie Guyot; Sophie Leduc; Roman Galetto; Sylvestre Grizot; Danusia Oficjalska; Christophe Perez; Fabien Delacôte; Aurélie Dupuy; Isabelle Chion-Sotinel; Diane Le Clerre; Céline Lebuhotel; Olivier Danos; Frédéric Lemaire; Kahina Oussedik; Frédéric Cédrone; Jean-Charles Epinat; Julianne Smith; Rafael J Yáñez-Muñoz; George Dickson; Linda Popplewell; Taeyoung Koo; Thierry VandenDriessche; Marinee K Chuah; Aymeric Duclert; Philippe Duchateau; Frédéric Pâques
Journal:  Nucleic Acids Res       Date:  2012-03-29       Impact factor: 16.971

7.  Nucleosomes correlate with in vivo progression pattern of de novo methylation of p16 CpG islands in human gastric carcinogenesis.

Authors:  Zhe-Ming Lu; Jing Zhou; Xiuhong Wang; Zhenpo Guan; Hua Bai; Zhao-Jun Liu; Na Su; Kaifeng Pan; Jiafu Ji; Dajun Deng
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

8.  Identification of Critical Elements for Regulation of Inorganic Pyrophosphatase (PPA1) in MCF7 Breast Cancer Cells.

Authors:  Dipti Ranjan Mishra; Sanjib Chaudhary; B Madhu Krishna; Sandip K Mishra
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

9.  SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2.

Authors:  Gaurav A Mehta; Steven P Angus; Christen A Khella; Kevin Tong; Pooja Khanna; Shelley A H Dixon; Michael P Verzi; Gary L Johnson; Michael L Gatza
Journal:  NPJ Breast Cancer       Date:  2021-04-09

10.  BRG1 promotes survival of UV-irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene.

Authors:  Srinivas V Saladi; Philip G Wong; Archit R Trivedi; Himangi G Marathe; Bridget Keenen; Shweta Aras; Zi-Qi Liew; Vijayasaradhi Setaluri; Ivana L de la Serna
Journal:  Pigment Cell Melanoma Res       Date:  2013-04-02       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.